Brachytherapy Alone May Be Sufficient for More Risky PCa Cases
The investigators observed no difference in mortality between BT alone and BT plus ADT and/or EBRT supplemental therapy.
Brachytherapy (BT) alone may be sufficient for treating unfavorable intermediate-risk prostate cancer (PCa), according to study findings published online ahead of print in Urologic Oncology.
BT alone is a well-established treatment modality for favorable intermediate-risk (FIR) PCa, but trimodal therapy consisting of BT, androgen-deprivation therapy (ADT), and external beam radiation therapy (EBRT) often is recommended for patients with unfavorable intermediate-risk (UIR) PCa, Martin T. King, MD, from Dana-Farber Cancer Institute and Brigham and Women's Hospital in Boston, and colleagues explained. In a study of 3723 patients with FIR and UIR PCa who received BT from 1997 to 2013, the FIR and UIR cohorts had median follow-up periods of 7.7 and 7.8 years, respectively. In both cohorts, the investigators observed no difference in PCa-specific mortality between BT alone and BT plus ADT and/or EBRT supplemental therapy.